5-Hydroxymethylfurfural Emerges as a Candidate Aggravator of Pulmonary Fibrosis
A common food-processing byproduct may do more than sit passively in the diet. In a new PLOS One study, 5-hydroxymethylfurfural (5-HMF) was linked to worse fibrotic lung injury in a mouse model of pulmonary fibrosis, with computational analyses and tissue experiments converging on several fibrosis-related molecular targets.
The investigators approached the question from two directions at once. They mined transcriptomic datasets from idiopathic pulmonary fibrosis and combined them with multiple target-prediction platforms for 5-HMF, then moved the most plausible signals into a bleomycin-induced mouse model. The result was not a single neat mechanism, but a pattern: 5-HMF aligned with genes and pathways already implicated in fibrosis, and in vivo exposure intensified injury rather than blunting it.
A Dietary Furan with Biological Reach
5-HMF is formed during thermal processing and storage of carbohydrate-rich foods and beverages, including coffee, bread, and fruit juices. It is also generated endogenously through the Maillard reaction and appears in tobacco smoke, which makes human exposure difficult to avoid entirely. The concern here is not that every exposure will trigger lung disease, but that a ubiquitous compound may interact with a lung environment already primed for aberrant repair.
Idiopathic pulmonary fibrosis remains one of the most difficult interstitial lung diseases to manage. The condition is marked by repetitive epithelial injury, fibroblast activation, and excessive extracellular matrix deposition. Once that repair program goes awry, the lung progressively loses compliance and gas-exchange capacity. Any environmental exposure that pushes those pathways further matters clinically, even if the effect size is modest.
Transcriptomic Signals Narrowed the Field
The computational workflow began with three public IPF transcriptomic datasets assembled into a discovery cohort, then balanced with two independent datasets for external validation. Differential expression analysis and weighted gene co-expression network analysis yielded 1,776 IPF-associated genes. In parallel, target mapping from TargetNet, SwissTargetPrediction, and PharmMapper produced 143 predicted 5-HMF targets.
The overlap was small but meaningful: 12 candidate targets sat at the intersection of the disease and chemical target sets. Enrichment analysis tied those genes to fibrosis-related pathways, including chemical carcinogenesis–receptor activation and estrogen signaling. The biological interpretation is not straightforward, but it does point toward a compound capable of engaging signaling programs that extend beyond a single receptor or one-off toxic interaction.
A machine-learning pipeline then prioritized seven core targets: CA2, CA4, ESR2, F10, HSP90AA1, PLA2G1B, and PTPRB. Blind docking suggested that 5-HMF could fit into the orthosteric pockets of all seven proteins, though the binding scores were weak and non-selective, ranging from −4.5 to −5.4 kcal/mol. Those scores do not establish pharmacologic potency. They do, however, support plausibility for multi-target engagement rather than a narrow single-protein effect.
Bleomycin-Exposed Mice Showed Clearer Injury After 5-HMF
The most clinically grounded findings came from the animal model. Mice with bleomycin-induced pulmonary fibrosis that also received 5-HMF developed more severe lung injury, more collagen deposition, and higher expression of several fibrosis-associated genes. The upregulated transcripts included Hsp90aa1, Pla2g1b, Ca4, F10, Acta2, and Col1a1.
This pattern matters because it moves the study beyond prediction. Acta2 and Col1a1 are canonical markers of myofibroblast activation and matrix accumulation, the exact processes that drive scar formation in fibrotic lung disease. Increased collagen deposition alongside those transcriptional changes is consistent with an intensified fibrotic response, not a transient inflammatory blip.
The signal was also not subtle. In the presence of bleomycin, 5-HMF aggravated lung injury rather than protecting the tissue. That direct divergence between the fibrotic and non-fibrotic condition is the main reason the study deserves attention: it suggests that an everyday dietary exposure may amplify an already vulnerable wound-healing program in the lung.
What the Molecular Pattern Suggests
Several of the prioritized genes hint at distinct biological routes into fibrosis. Carbonic anhydrases such as CA2 and CA4 can influence tissue pH and microenvironmental signaling. ESR2 raises the possibility of hormonal or steroid-related modulation. HSP90AA1 points toward stress-response and protein-folding pathways. PLA2G1B and F10 suggest inflammatory and coagulation-linked biology, both of which can participate in tissue remodeling and fibroproliferation.
The study did not claim that any one target explains the phenotype on its own. Instead, it framed 5-HMF as a compound with multiple low-affinity interactions that may converge on fibrotic signaling networks. For translational readers, that is the more realistic model. Environmental toxicants rarely behave like clean single-target ligands; they more often exert weak but cumulative pressure across pathways that are already dysregulated.
Clinical Caution Without Overreach
The findings do not show that 5-HMF independently causes idiopathic pulmonary fibrosis in humans. The bleomycin model reflects fibrotic injury, not spontaneous disease initiation, and the docking results were weak. Human dietary exposure levels were not measured in this study, and no epidemiologic association was established.
Still, the work raises a plausible concern for patients who already have fibrotic lung disease or are at risk for it. If a common food-derived compound can worsen experimental fibrosis, then exposure assessment becomes relevant to respiratory toxicology and to the broader question of which everyday chemicals may alter disease trajectory.
Why the Study Stops Short of Causality
The investigators were careful to frame the work as hypothesis-generating. Their own data support a role for 5-HMF in aggravating fibrotic injury, but they did not prove that it initiates fibrosis from scratch. They also did not resolve whether the observed effects depend on dose, timing, metabolism, or a specific lung-cell population.
Those unanswered points define the next layer of research. Longer exposure studies, quantitative dose-response work, and human biomarker data would be needed before any dietary or public-health recommendation could follow. For now, the study places 5-HMF on the map as a biologically plausible modifier of pulmonary fibrosis rather than a proven cause, and the mouse data make that signal difficult to ignore.